(Q38566022)

4 September 2017

title

Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy (English)

1 reference

4 September 2017

Stacey B Trooskin

1

1 reference

4 September 2017

Helen Reynolds

series ordinal

2

1 reference

4 September 2017

Jay R Kostman

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

12 August 2015

1 reference

Clinical Infectious Diseases

4 September 2017

published in

1 reference

4 September 2017

volume

61

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

1825-1830

1 reference

Treatment of hepatitis C: a systematic review

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Hepatitis C beware--the end is nigh

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Hepatitis C drugs not reaching poor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Chronic hepatitis C virus (HCV) disease burden and cost in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Hepatitis C virus infection in USA: an estimate of true prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Can hepatitis C be eradicated in the United States?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Perspective: test and treat this silent killer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Responding to hepatitis C through the criminal justice system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Emerging lessons from the drug effectiveness review project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Hepatitis C virus reinfection following treatment among people who use drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

IFN- alpha blocks IL-17 production by peripheral blood mononuclear cells in patients with chronic active hepatitis B Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

New Expensive Treatments for Hepatitis C Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV677

21 January 2018

Identifiers

DOI

10.1093/CID/CIV677

1 reference

4 September 2017

1 reference